<p>週五午盤交易時，天境生物（NASDAQ:IMAB）股價下跌了 3.8%。股價最低觸及 1.23 美元，最後交易價為 1.26 美元。約有 150,879 股在交易中換手，較平均每日成交量 345,044 股下降了 56%。該股之前收盤價為 1.31 美元。</p>
<h2>華爾街分析師觀點</h2>
<p>Needham &amp; Company LLC 單獨重申了對天境生物股票的 “買入” 評級，並設定了 6.00 美元的目標價。這是在 4 月 12 日星期五的一份研究報告中提到的。</p>
<p><strong>閲讀我們對天境生物的最新分析</strong></p>
<h2>天境生物股價下跌 3.8%</h2>
<p>該股的 50 天簡單移動平均線為 1.63 美元，200 天簡單移動平均線為 1.73 美元。</p>
<h2>對天境生物的對沖基金觀點</h2>
<p>一家對沖基金最近在天境生物股票中新建了一個持股。根據該公司最近向美國證券交易委員會提交的文件，abrdn plc 在第四季度購入了天境生物 162,580 股，價值約 309,000 美元。截至最近一次提交給美國證券交易委員會的文件，abrdn plc 持有天境生物 0.20% 的股份。目前有 38.38% 的股份由機構投資者和對沖基金持有。</p>
<h2>關於天境生物</h2>
<p>天境生物是一家臨牀階段的生物製藥公司，致力於發現、開發和商業化生物製劑以治療癌症和自身免疫性疾病。該公司正在開發 Felzartamab，一種用於治療膜性腎病患者的 CD38 抗體，目前處於 1b/2a 期；Eftansomatropin alfa，一種長效生長激素，已完成 3 期臨牀試驗，用於治療兒童生長激素缺乏症；Efineptakin alfa，一種重組人 IL-7，用於治療癌症相關淋巴細胞減少和癌症免疫治療，目前處於 2 期；以及 Lemzoparlimab，一種 CD47 單克隆抗體，已完成 2 期臨牀試驗。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們比天境生物更喜歡的股票</li>
<li>現在購買寶潔股票，趁它創下歷史新高之前</li>
<li>你應該投資比特幣嗎？利弊分析</li>
<li>內部買盤解讀：投資者需要了解的事項</li>
<li>亞馬遜股票在人工智能泡沫破裂後有望強勢反彈</li>
<li>如何選擇評級最高的股票</li>
<li>殼牌股票：石油和天然氣巨頭致力於回購和股息</li>
</ul>
<p><em>此即時新聞警報由敍事科技和 MarketBeat 的財務數據生成，旨在為讀者提供最快速和準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
<p>→ 能源行業每月股息的最大機會（來自 Investors Alley）(廣告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDI0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDI0"/></p>
<h2>現在是否值得投資 1,000 美元購買天境生物？</h2>
<p>在考慮天境生物之前，您應該聽聽這個。</p>
<p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已確定了五隻頂級分析師悄悄告訴客户現在購買的股票，然後再廣泛市場注意到之前...而天境生物不在這份名單上。</p>
<p>儘管天境生物目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

天境生物

<p>天境生物（NASDAQ:IMAB）股價在週五的午間交易中下跌了 3.8%。該股票的 50 天簡單移動平均線為$1.63，200 天簡單移動平均線為$1.73。一家對沖基金最近新建了一筆在天境生物股票中的持股。天境生物是一家臨牀階段生物製藥公司，致力於開發生物製劑治療癌症和自身免疫性疾病</p>

<p>I-Mab (NASDAQ:IMAB - Get Free Report) shares dropped 3.8% during mid-day trading on Friday . The stock traded as low as $1.23 and last traded at $1.26. Approximately 150,879 shares changed hands during trading, a decline of 56% from the average daily volume of 345,044 shares. The stock had previously closed at $1.31.</p>
<div class="lb-trans"><p>週五午盤交易時，天境生物（NASDAQ:IMAB）股價下跌了 3.8%。股價最低觸及 1.23 美元，最後交易價為 1.26 美元。約有 150,879 股在交易中換手，較平均每日成交量 345,044 股下降了 56%。該股之前收盤價為 1.31 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Separately, Needham &amp; Company LLC reissued a &#34;buy&#34; rating and set a $6.00 target price on shares of I-Mab in a research note on Friday, April 12th.</p>
<div class="lb-trans"><p>Needham &amp; Company LLC 單獨重申了對天境生物股票的 “買入” 評級，並設定了 6.00 美元的目標價。這是在 4 月 12 日星期五的一份研究報告中提到的。</p>
</div><p><strong>Read Our Latest Analysis on I-Mab</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對天境生物的最新分析</strong></p>
</div><h2>I-Mab Stock Down 3.8 %</h2>
<div class="lb-trans"><h2>天境生物股價下跌 3.8%</h2>
</div><p>The stock has a 50 day simple moving average of $1.63 and a 200-day simple moving average of $1.73.</p>
<div class="lb-trans"><p>該股的 50 天簡單移動平均線為 1.63 美元，200 天簡單移動平均線為 1.73 美元。</p>
</div><h2>Hedge Funds Weigh In On I-Mab</h2>
<div class="lb-trans"><h2>對天境生物的對沖基金觀點</h2>
</div><p>A hedge fund recently bought a new stake in I-Mab stock. abrdn plc bought a new position in I-Mab (NASDAQ:IMAB - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 162,580 shares of the company's stock, valued at approximately $309,000. abrdn plc owned 0.20% of I-Mab as of its most recent filing with the SEC. 38.38% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一家對沖基金最近在天境生物股票中新建了一個持股。根據該公司最近向美國證券交易委員會提交的文件，abrdn plc 在第四季度購入了天境生物 162,580 股，價值約 309,000 美元。截至最近一次提交給美國證券交易委員會的文件，abrdn plc 持有天境生物 0.20% 的股份。目前有 38.38% 的股份由機構投資者和對沖基金持有。</p>
</div><h2>About I-Mab (Get Free Report)</h2>
<div class="lb-trans"><h2>關於天境生物</h2>
</div><p>I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial.</p>
<div class="lb-trans"><p>天境生物是一家臨牀階段的生物製藥公司，致力於發現、開發和商業化生物製劑以治療癌症和自身免疫性疾病。該公司正在開發 Felzartamab，一種用於治療膜性腎病患者的 CD38 抗體，目前處於 1b/2a 期；Eftansomatropin alfa，一種長效生長激素，已完成 3 期臨牀試驗，用於治療兒童生長激素缺乏症；Efineptakin alfa，一種重組人 IL-7，用於治療癌症相關淋巴細胞減少和癌症免疫治療，目前處於 2 期；以及 Lemzoparlimab，一種 CD47 單克隆抗體，已完成 2 期臨牀試驗。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than I-Mab</li>
<li>Buy P&amp;G Now, Before It Sets A New All-Time High</li>
<li>Should You Invest in Bitcoin? Pros and Cons</li>
<li>Insider Buying Explained: What Investors Need to Know</li>
<li>Amazon Stock is Primed to Rebound Strongly After AI Bubble Bursts</li>
<li>How to Choose Top Rated Stocks</li>
<li>Shell Stock: Oil &amp; Gas Giant Committed to Buybacks and Dividends</li>
</ul>
<div class="lb-trans"><h2>精選文章</h2>
<ul>
<li>五隻我們比天境生物更喜歡的股票</li>
<li>現在購買寶潔股票，趁它創下歷史新高之前</li>
<li>你應該投資比特幣嗎？利弊分析</li>
<li>內部買盤解讀：投資者需要了解的事項</li>
<li>亞馬遜股票在人工智能泡沫破裂後有望強勢反彈</li>
<li>如何選擇評級最高的股票</li>
<li>殼牌股票：石油和天然氣巨頭致力於回購和股息</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍事科技和 MarketBeat 的財務數據生成，旨在為讀者提供最快速和準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><p>→ Biggest opportunity for monthly dividends in the energy sector (From Investors Alley)(Ad)</p>
<div class="lb-trans"><p>→ 能源行業每月股息的最大機會（來自 Investors Alley）(廣告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDI0" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9024&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in I-Mab right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資 1,000 美元購買天境生物？</h2>
</div><p>Before you consider I-Mab, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮天境生物之前，您應該聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and I-Mab wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已確定了五隻頂級分析師悄悄告訴客户現在購買的股票，然後再廣泛市場注意到之前...而天境生物不在這份名單上。</p>
</div><p>While I-Mab currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管天境生物目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

天境生物（NASDAQ:IMAB）股價下跌 3.8%